Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA

被引:36
|
作者
Quan, V [1 ]
Towey, M [1 ]
Sacks, S [1 ]
Kelly, AP [1 ]
机构
[1] Guys Kings & St Thomas Sch Med, Dept Nephrol, London, England
基金
英国惠康基金;
关键词
CIITA; MHC; class II; bare lymphocyte syndrome; transcription;
D O I
10.1007/s002510050579
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
We investigated the underlying genetic defect in an immunodeficient patient who presented with recurrent bacterial infections in his late twenties and demonstrated a transcriptional defect in major histocompatibility complex (MHC) class II regulation. Transient heterokaryon analysis implicated functional loss of CIITA, the MHC class II transactivator protein, and in support of this MHC class II antigen expression was restored by stable transfection with the wild-type molecule, A single amino acid substitution, phenylalanine to serine, in the COOT-I-terminal portion of the CIITA sequence correlated with reduced transcription of both classical (HLA-DP, -DQ, and -DR) and nonclassical (HLA-DM and -DO) class II genes. The long survival of the patient, although remarkable, was not associated with partial CIITA function as evidenced by residual MHC class II expression. These data define at high resolution a region of CIITA that is essential for function in both professional and nonprofessional antigen presenting cells and which could potentially constitute a target for therapeutic intervention by novel factors with a propensity to downregulate MHC class II antigen expression.
引用
收藏
页码:957 / 963
页数:7
相关论文
共 50 条
  • [21] Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A
    Bontron, S
    Steimle, V
    Ucla, C
    Eibl, MM
    Mach, B
    HUMAN GENETICS, 1997, 99 (04) : 541 - 546
  • [22] Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A
    Séverine Bontron
    V. Steimle
    Catherine Ucla
    Martha M. Eibl
    B. Mach
    Human Genetics, 1997, 99 : 541 - 546
  • [23] Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene
    Peijnenburg, A
    Van den Berg, R
    Van Eggermond, MJCA
    Sanal, Ö
    Vossen, JMJJ
    Lennon, AM
    Alcaïde-Loridan, C
    Van den Elsen, PJ
    IMMUNOGENETICS, 2000, 51 (01) : 42 - 49
  • [24] Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene
    A. Peijnenburg
    R. Van den Berg
    M.J.C.A. Van Eggermond
    Ö. Sanal
    J. M. J. J. Vossen
    A. -M. Lennon
    C. Alcaïde-Loridan
    P.J. Van den Elsen
    Immunogenetics, 2000, 51 : 42 - 49
  • [25] REGULATION OF MHC CLASS-II EXPRESSION BY INTERFERON-GAMMA MEDIATED BY THE TRANSACTIVATOR GENE CIITA
    STEIMLE, V
    SIEGRIST, CA
    MOTTET, A
    LISOWSKAGROSPIERRE, B
    MACH, B
    SCIENCE, 1994, 265 (5168) : 106 - 109
  • [26] Control of tumor growth in vivo by gene therapy with the MHC class II transactivator CIITA
    Meazza, R
    Comes, A
    Barbaro, AD
    Tosi, G
    Ferrini, S
    Accolla, R
    TISSUE ANTIGENS, 2002, 59 : 5 - 5
  • [27] MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
    Christian Steidl
    Sohrab P. Shah
    Bruce W. Woolcock
    Lixin Rui
    Masahiro Kawahara
    Pedro Farinha
    Nathalie A. Johnson
    Yongjun Zhao
    Adele Telenius
    Susana Ben Neriah
    Andrew McPherson
    Barbara Meissner
    Ujunwa C. Okoye
    Arjan Diepstra
    Anke van den Berg
    Mark Sun
    Gillian Leung
    Steven J. Jones
    Joseph M. Connors
    David G. Huntsman
    Kerry J. Savage
    Lisa M. Rimsza
    Douglas E. Horsman
    Louis M. Staudt
    Ulrich Steidl
    Marco A. Marra
    Randy D. Gascoyne
    Nature, 2011, 471 : 377 - 381
  • [28] MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
    Steidl, Christian
    Shah, Sohrab P.
    Woolcock, Bruce W.
    Rui, Lixin
    Kawahara, Masahiro
    Farinha, Pedro
    Johnson, Nathalie A.
    Zhao, Yongjun
    Telenius, Adele
    Ben Neriah, Susana
    McPherson, Andrew
    Meissner, Barbara
    Okoye, Ujunwa C.
    Diepstra, Arjan
    van den Berg, Anke
    Sun, Mark
    Leung, Gillian
    Jones, Steven J.
    Connors, Joseph M.
    Huntsman, David G.
    Savage, Kerry J.
    Rimsza, Lisa M.
    Horsman, Douglas E.
    Staudt, Louis M.
    Steidl, Ulrich
    Marra, Marco A.
    Gascoyne, Randy D.
    NATURE, 2011, 471 (7338) : 377 - +
  • [29] Control of tumor growth in vivo by gene therapy with the MHC class II transactivator CIITA
    Comes, A
    Meazza, R
    Tosi, G
    Barbaro, AD
    Ferrini, S
    Accolla, RS
    FASEB JOURNAL, 2000, 14 (06): : A1001 - A1001
  • [30] A possible role of interferon consensus sequence binding protein (ICSBP) in regulating MHC class II expression through class II transactivator (CIITA).
    Konig, S
    Schmidt, M
    Alfken, J
    Hoppe, G
    Nagel, S
    Horak, I
    Levi, BZ
    Neubauer, A
    Wittig, B
    BLOOD, 1997, 90 (10) : 3445 - 3445